PRESS RELEASE published on 03/14/2023 at 22:40, 3 years 7 months ago Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
PRESS RELEASE published on 03/10/2023 at 17:00, 3 years 7 months ago Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
PRESS RELEASE published on 02/28/2023 at 13:30, 3 years 8 months ago Moderna to Present at Cowen's 43rd Annual Health Care Conference
PRESS RELEASE published on 02/23/2023 at 13:00, 3 years 8 months ago Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
PRESS RELEASE published on 02/22/2023 at 22:05, 3 years 8 months ago Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Mela
PRESS RELEASE published on 02/22/2023 at 13:00, 3 years 8 months ago Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
PRESS RELEASE published on 02/17/2023 at 17:00, 3 years 8 months ago Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
PRESS RELEASE published on 02/16/2023 at 22:05, 3 years 8 months ago Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
PRESS RELEASE published on 02/02/2023 at 13:00, 3 years 9 months ago Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
PRESS RELEASE published on 01/30/2023 at 13:15, 3 years 9 months ago Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
Published on 11/10/2026 at 13:30, 2 minutes ago Adcore Reports Third Quarter 2026 Results: Gross Margin Rises to 64%, Operating Loss Halved, Cash Up to $4.3 Million as Restructuring Takes Hold
Published on 11/10/2026 at 13:15, 17 minutes ago Evergold Intersects 41.0 Metres of 1.10 g/t AuEq and 31.9 Metres of 1.43 g/t AuEq on New Northern Fence, Extending Mineralization North at Golden Lion
Published on 11/10/2026 at 13:00, 32 minutes ago Zeb Nickel Commences Diamond Drilling at the Zeb Nickel Project
Published on 11/10/2026 at 13:00, 32 minutes ago Electrovaya to Participate in Upcoming Investor Conferences
Published on 11/10/2026 at 13:00, 32 minutes ago INEO Invited to 15th Annual ROTH Technology Conference in New York
Published on 11/10/2026 at 13:05, 26 minutes ago NORTON MOTORCYCLES ENTERS NEW CATEGORY WITH NEW NORTON 450 CC URBAN DEBUT AT EICMA - FULL MATERIALS NOW AVAILABLE
Published on 11/10/2026 at 13:00, 32 minutes ago Oakstone Holidays Champions Off-Season Coastal Escapes as UK Holidaymakers Rethink Seaside Breaks
Published on 11/10/2026 at 12:50, 42 minutes ago Form 8.3 - Zürcher Kantonalbank: Irish Residential Properties REIT plc
Published on 11/10/2026 at 12:45, 47 minutes ago Gabler Group AG Invites to Earnings Call on Unaudited Q3 2026 Results
Published on 11/10/2026 at 12:35, 56 minutes ago Cognizant dedicates more than 25,000 professionals to Claude delivery, introduces managed services model to run Claude at the core of enterprise operations
Published on 11/10/2026 at 11:02, 2 hours 29 minutes ago Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 11:02, 2 hours 29 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of October 31, 2026
Published on 11/10/2026 at 07:00, 6 hours 32 minutes ago bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/10/2026 at 07:00, 6 hours 32 minutes ago bioMérieux obtient l’autorisation 510(k) de la FDA américaine et le marquage CE selon l’IVDR pour VITEK® PRO, son nouvel instrument automatisé d’identification et d’antibiogramme contribuant à la lutte contre l’antibiorésistance
Published on 11/09/2026 at 18:30, 19 hours 2 minutes ago Air Liquide has successfully issued a CHF 390 million multi-tranche bond
